BACKGROUND: Serotonin type 3 receptor (5-HT3 R) antagonists are potentially useful therapeutic agents for diarrhea-predominant irritable bowel syndrome (IBS-D). To identify biomarkers predicting effectiveness of the 5-HT3 R antagonist (ramosetron) in IBS-D. METHODS: Irritable bowel syndrome-D Japanese subjects received 2.5 or 5 μg of ramosetron once daily for 4 weeks. Colonic mucosal S100A and tryptophan hydroxylase (TPH) mRNA expression levels were measured before treatment. Genomic DNA was extracted from blood and polymorphisms of TPH1 and TPH2 were analyzed. KEY RESULTS: Forty-two patients (27 men and 15 women, mean age 42 years) with IBS-D were included for analysis. Improvement of IBS symptoms was seen in 26 (61.9%). Baseline S100A10 (p = 0.02) and TPH1 (p = 0.02) expression were significantly higher in the ramosetron responders than in the non-responders. The frequencies of the TPH1 rs4537731G allele in linkage disequilibrium with the TPH1 rs7130929 T allele (11.5% vs 50%, p = 0.003; OR: 12; 95% CI: 2.1-69) along with TPH1 rs211105 C allele (3.8% vs 43.8%, p = 0.0003; OR: 19; 95% CI: 2.1-181) were significantly lower in the responders than in the non-responders. The mean scores of diarrhea at baseline were significantly higher (5.2 vs 3.7, p = 0.005) in patients with TPH1 rs211105 T/T than those with the G allele. CONCLUSIONS & INFERENCES: TPH1 gene polymorphisms and S100A10 expression, which correlate with 5-HT signaling were associated with ramosetron effectiveness in IBS-D, and may possibly lead to prospective identification of the resistance to treatment.
BACKGROUND:Serotonin type 3 receptor (5-HT3 R) antagonists are potentially useful therapeutic agents for diarrhea-predominant irritable bowel syndrome (IBS-D). To identify biomarkers predicting effectiveness of the 5-HT3 R antagonist (ramosetron) in IBS-D. METHODS:Irritable bowel syndrome-D Japanese subjects received 2.5 or 5 μg of ramosetron once daily for 4 weeks. Colonic mucosalS100A and tryptophan hydroxylase (TPH) mRNA expression levels were measured before treatment. Genomic DNA was extracted from blood and polymorphisms of TPH1 and TPH2 were analyzed. KEY RESULTS: Forty-two patients (27 men and 15 women, mean age 42 years) with IBS-D were included for analysis. Improvement of IBS symptoms was seen in 26 (61.9%). Baseline S100A10 (p = 0.02) and TPH1 (p = 0.02) expression were significantly higher in the ramosetron responders than in the non-responders. The frequencies of the TPH1 rs4537731G allele in linkage disequilibrium with the TPH1 rs7130929 T allele (11.5% vs 50%, p = 0.003; OR: 12; 95% CI: 2.1-69) along with TPH1rs211105 C allele (3.8% vs 43.8%, p = 0.0003; OR: 19; 95% CI: 2.1-181) were significantly lower in the responders than in the non-responders. The mean scores of diarrhea at baseline were significantly higher (5.2 vs 3.7, p = 0.005) in patients with TPH1rs211105 T/T than those with the G allele. CONCLUSIONS & INFERENCES: TPH1 gene polymorphisms and S100A10 expression, which correlate with 5-HT signaling were associated with ramosetron effectiveness in IBS-D, and may possibly lead to prospective identification of the resistance to treatment.
Authors: M Harvey; E Shink; M Tremblay; B Gagné; C Raymond; M Labbé; D J Walther; M Bader; N Barden Journal: Mol Psychiatry Date: 2004-11 Impact factor: 15.992
Authors: Michael Camilleri; Christopher N Andrews; Adil E Bharucha; Paula J Carlson; Irene Ferber; Debra Stephens; Thomas C Smyrk; Raul Urrutia; Jeroen Aerssens; Leen Thielemans; Hinrich Göhlmann; Ilse van den Wyngaert; Bernard Coulie Journal: Gastroenterology Date: 2006-11-17 Impact factor: 22.682
Authors: Philip M Brown; Douglas A Drossman; Alastair J J Wood; Gary A Cline; Kenny S Frazier; Jessica I Jackson; Johanna Bronner; Joel Freiman; Brian Zambrowicz; Arthur Sands; Michael D Gershon Journal: Gastroenterology Date: 2011-05-18 Impact factor: 22.682
Authors: Angèle P M Kerckhoffs; José J M ter Linde; Louis M A Akkermans; Melvin Samsom Journal: Am J Physiol Gastrointest Liver Physiol Date: 2012-02-09 Impact factor: 4.052
Authors: Bryan E Essien; Helmut Grasberger; Rachael D Romain; David J Law; Natalia A Veniaminova; Milena Saqui-Salces; Mohamad El-Zaatari; Arthur Tessier; Michael M Hayes; Alexander C Yang; Juanita L Merchant Journal: Gastroenterology Date: 2013-02-07 Impact factor: 22.682
Authors: Paul Enck; Qasim Aziz; Giovanni Barbara; Adam D Farmer; Shin Fukudo; Emeran A Mayer; Beate Niesler; Eamonn M M Quigley; Mirjana Rajilić-Stojanović; Michael Schemann; Juliane Schwille-Kiuntke; Magnus Simren; Stephan Zipfel; Robin C Spiller Journal: Nat Rev Dis Primers Date: 2016-03-24 Impact factor: 52.329
Authors: David Gunn; Ron Fried; Rabia Lalani; Amanda Farrin; Ivana Holloway; Tom Morris; Catherine Olivier; Rachael Kearns; Maura Corsetti; Mark Scott; Adam Farmer; Anton Emmanuel; Peter Whorwell; Yan Yiannakou; David Sanders; John Mclaughlin; Kapil Kapur; Maria Eugenicos; Ayesha Akbar; Nigel Trudgill; Lesley Houghton; Phil G Dinning; Alexander C Ford; Qasim Aziz; Robin Spiller Journal: Trials Date: 2019-08-20 Impact factor: 2.279
Authors: Jadwiga Snarska; Ewa Fiedorowicz; Dominika Rozmus; Konrad Wroński; Maria Latacz; Natalia Kordulewska; Janusz Płomiński; Roman Grzybowski; Huub F J Savelkoul; Elżbieta Kostyra; Anna Cieślińska Journal: BMC Gastroenterol Date: 2021-11-12 Impact factor: 3.067